Cadrenal Therapeutics Q3 2025 net loss $2.7M; advances tecarfarin and frunexian pipeline

Cadrenal Therapeutics, Inc.

2025-Q3 EPS reported -$5.23

Net loss of $2.7M for Q3 2025 vs $2.4M in Q3 2024; cash and equivalents $3.9M as of Sept 30.
R&D expense $0.7M (down from $0.8M); G&A expense $2.0M (up from $1.7M) year-over-year.
Completed cGMP manufacturing of tecarfarin; ongoing Phase 2 LVAD study with Abbott.
Acquired eXIthera Pharmaceuticals assets in Sept 2025, including frunexian, a Phase 2-ready IV Factor XIa inhibitor.
~2.1M common shares outstanding as of Sept 30, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.